These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

173 related items for PubMed ID: 36479136

  • 1. Pretreatment Pan-Immune-Inflammation Value Efficiently Predicts Survival Outcomes in Glioblastoma Multiforme Patients Receiving Radiotherapy and Temozolomide.
    Topkan E, Kucuk A, Selek U.
    J Immunol Res; 2022; 2022():1346094. PubMed ID: 36479136
    [Abstract] [Full Text] [Related]

  • 2. Prognostic Value of Pretreatment Systemic Immune-Inflammation Index in Glioblastoma Multiforme Patients Undergoing Postneurosurgical Radiotherapy Plus Concurrent and Adjuvant Temozolomide.
    Topkan E, Besen AA, Ozdemir Y, Kucuk A, Mertsoylu H, Pehlivan B, Selek U.
    Mediators Inflamm; 2020; 2020():4392189. PubMed ID: 32565725
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. High pre-chemoradiotherapy pan-immune-inflammation value levels predict worse outcomes in patients with stage IIIB/C non-small-cell lung cancer.
    Topkan E, Kucuk A, Ozkan EE, Ozturk D, Besen AA, Mertsoylu H, Pehlivan B, Selek U.
    Discov Oncol; 2023 Dec 13; 14(1):230. PubMed ID: 38091179
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Assessing the prognostic role of panimmune inflammation in high-grade gliomas.
    Kavak EE, Dilli İ, Yavaş G.
    Clin Transl Oncol; 2024 Aug 14. PubMed ID: 39141278
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles.
    Barbagallo GM, Paratore S, Caltabiano R, Palmucci S, Parra HS, Privitera G, Motta F, Lanzafame S, Scaglione G, Longo A, Albanese V, Certo F.
    Neurosurg Focus; 2014 Dec 14; 37(6):E4. PubMed ID: 25434389
    [Abstract] [Full Text] [Related]

  • 13. Patterns of recurrence and outcomes of glioblastoma multiforme treated with chemoradiation and adjuvant temozolomide.
    Faustino AC, Viani GA, Hamamura AC.
    Clinics (Sao Paulo); 2020 Dec 14; 75():e1553. PubMed ID: 32935821
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. The global immune-nutrition-inflammation index (GINI) as a robust prognostic factor in glioblastoma patients treated with the standard stupp protocol.
    Topkan E, Kilic Durankus N, Senyurek S, Öztürk D, Besen AA, Mertsoylu H, Pehlivan B, Selek U.
    Int J Immunopathol Pharmacol; 2024 Dec 14; 38():3946320241284089. PubMed ID: 39305006
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Prognostic value of the Glasgow Prognostic Score for glioblastoma multiforme patients treated with radiotherapy and temozolomide.
    Topkan E, Selek U, Ozdemir Y, Yildirim BA, Guler OC, Ciner F, Mertsoylu H, Tufan K.
    J Neurooncol; 2018 Sep 14; 139(2):411-419. PubMed ID: 29696530
    [Abstract] [Full Text] [Related]

  • 20. The added value of concurrently administered temozolomide versus adjuvant temozolomide alone in newly diagnosed glioblastoma.
    Sher DJ, Henson JW, Avutu B, Hochberg FH, Batchelor TT, Martuza RL, Barker FG, Loeffler JS, Chakravarti A.
    J Neurooncol; 2008 May 14; 88(1):43-50. PubMed ID: 18231723
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.